Argenx
ARGX
#571
Rank
NZ$62.06 B
Marketcap
$1,038
Share price
1.54%
Change (1 day)
27.03%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Argenx (ARGX) Fails to deliver data

Key failure to deliver metrics for Argenx :

A Failure to deliver also known as fails-to-deliver or FTD occurs when a buyer or seller is unable to meet his trading obligations. FTDs for US listed companies are reported to the SEC and published twice a month. Therefore there is a certain delay between the reporting and the publishing of the data.

Failures to deliver for Argenx (ARGX) - 3 months history

Number of shares, 3 months chart

Biweekly Failures to deliver volume for Argenx (ARGX) - since 2017

Volume in USD (price x number of shares), data since 2017

Argenx (ARGX) Failure to deliver volume, Year over Year

Year Volume (Price x Shares) Change
2024NZ$32.3 M71.93%
2023NZ$18.79 M-94.36%
2022NZ$0.33 B866.49%
2021NZ$34.48 M44.9%
2020NZ$23.79 M-7.86%
2019NZ$25.82 M75.29%
2018NZ$14.73 M-48.76%
2017NZ$28.75 M